Switch theme
Sign up to access all valuation multiples
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
1900
114K+
LTM Revenue $43.1B
LTM EBITDA $11.2B
$238B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Abbott Laboratories has a last 12-month revenue of $43.1B and a last 12-month EBITDA of $11.2B.
In the most recent fiscal year, Abbott Laboratories achieved revenue of $42.0B and an EBITDA of $10.8B.
Abbott Laboratories expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Abbott Laboratories valuation multiples based on analyst estimates| LTM | NTM | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | $43.1B | XXX | XXX | XXX | XXX |
| Gross Profit | $24.3B | XXX | XXX | XXX | XXX |
| Gross Margin | 56% | XXX | XXX | XXX | XXX |
| EBITDA | $11.2B | XXX | XXX | XXX | XXX |
| EBITDA Margin | 26% | XXX | XXX | XXX | XXX |
| EBIT | $9.8B | XXX | XXX | XXX | XXX |
| EBIT Margin | 23% | XXX | XXX | XXX | XXX |
| Net Profit | $8.5B | XXX | XXX | XXX | XXX |
| Net Margin | 20% | XXX | XXX | XXX | XXX |
| Net Debt | $6.5B | XXX | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Abbott Laboratories's stock price is $133.
Abbott Laboratories has current market cap of $231B, and EV of $238B.
See Abbott Laboratories trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $238B | $231B | XXX | XXX | XXX | XXX | $4.87 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Abbott Laboratories has market cap of $231B and EV of $238B.
Abbott Laboratories's trades at 5.5x EV/LTM Revenue multiple, and 21.2x EV/LTM EBITDA.
Equity research analysts estimate Abbott Laboratories's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Abbott Laboratories has a P/E ratio of 27.1x.
See valuation multiples for Abbott Laboratories and 10K+ public comps| LTM | NTM | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Market cap (current) | $231B | XXX | XXX | XXX | XXX |
| EV (current) | $238B | XXX | XXX | XXX | XXX |
| EV/Revenue | 5.5x | XXX | XXX | XXX | XXX |
| EV/EBITDA | 21.2x | XXX | XXX | XXX | XXX |
| EV/EBIT | 24.3x | XXX | XXX | XXX | XXX |
| EV/Gross Profit | 9.8x | XXX | XXX | XXX | XXX |
| P/E | 27.1x | XXX | XXX | XXX | XXX |
| EV/FCF | 26.5x | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAbbott Laboratories's last 12 month revenue growth is 7%
Abbott Laboratories's revenue per employee for the last 12 months averaged $0.4M, while opex per employee averaged $0.1M for the same period.
Abbott Laboratories's rule of 40 is 33% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Abbott Laboratories's rule of X is 43% (another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Abbott Laboratories and other 10K+ public comps| LTM | NTM | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue Growth | 7% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 26% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 11% | XXX | XXX | XXX | XXX |
| Rule of 40 | 33% | XXX | XXX | XXX | XXX |
| Bessemer Rule of X | 43% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.4M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 7% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 39% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Abbott Laboratories acquired XXX companies to date.
Last acquisition by Abbott Laboratories was XXXXXXXX, XXXXX XXXXX XXXXXX . Abbott Laboratories acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Abbott Laboratories founded? | Abbott Laboratories was founded in 1900. |
| Where is Abbott Laboratories headquartered? | Abbott Laboratories is headquartered in United States of America. |
| How many employees does Abbott Laboratories have? | As of today, Abbott Laboratories has 114K+ employees. |
| Who is the CEO of Abbott Laboratories? | Abbott Laboratories's CEO is Mr. Robert B. Ford. |
| Is Abbott Laboratories publicy listed? | Yes, Abbott Laboratories is a public company listed on NYS. |
| What is the stock symbol of Abbott Laboratories? | Abbott Laboratories trades under ABT ticker. |
| When did Abbott Laboratories go public? | Abbott Laboratories went public in 1949. |
| Who are competitors of Abbott Laboratories? | Similar companies to Abbott Laboratories include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Abbott Laboratories? | Abbott Laboratories's current market cap is $231B |
| What is the current revenue of Abbott Laboratories? | Abbott Laboratories's last 12 months revenue is $43.1B. |
| What is the current revenue growth of Abbott Laboratories? | Abbott Laboratories revenue growth (NTM/LTM) is 7%. |
| What is the current EV/Revenue multiple of Abbott Laboratories? | Current revenue multiple of Abbott Laboratories is 5.5x. |
| Is Abbott Laboratories profitable? | Yes, Abbott Laboratories is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Abbott Laboratories? | Abbott Laboratories's last 12 months EBITDA is $11.2B. |
| What is Abbott Laboratories's EBITDA margin? | Abbott Laboratories's last 12 months EBITDA margin is 26%. |
| What is the current EV/EBITDA multiple of Abbott Laboratories? | Current EBITDA multiple of Abbott Laboratories is 21.2x. |
| What is the current FCF of Abbott Laboratories? | Abbott Laboratories's last 12 months FCF is $9.0B. |
| What is Abbott Laboratories's FCF margin? | Abbott Laboratories's last 12 months FCF margin is 21%. |
| What is the current EV/FCF multiple of Abbott Laboratories? | Current FCF multiple of Abbott Laboratories is 26.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
